Nexium Buyers Urge Judge To Rethink Ranbaxy Win In MDL

Law360, New York (March 3, 2014, 3:47 PM EST) -- New evidence from the U.S. Food and Drug Administration shows that Ranbaxy Inc. could have received approval for a generic version of heartburn drug Nexium far sooner than it did, direct purchasers told a Massachusetts federal judge on Friday in a bid to revive their pay-for-delay suit against the drugmaker.

The direct purchaser plaintiffs, which include wholesalers and retailers, argue in a motion for reconsideration that newly released FDA documents show the agency could have allowed Ranbaxy to attain approval for a generic version of AstraZeneca...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.